Cargando…

The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial

BACKGROUND: Type 2 diabetes is a kind of metabolic disease. Its clinical characteristic is hyperglycemia. Recently, more and more elderly people suffer from type 2 diabetes, and the glycemic variability of the elderly is greater. In addition, blood sugar variation is more likely to cause diabetes co...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Dongqi, Zhang, Li, Han, Xuke, Gao, Yang, Zeng, Min, Yu, Weiwei, Sun, Lisha, Chen, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402745/
https://www.ncbi.nlm.nih.gov/pubmed/32756078
http://dx.doi.org/10.1097/MD.0000000000020750
_version_ 1783566813176528896
author Zhou, Dongqi
Zhang, Li
Han, Xuke
Gao, Yang
Zeng, Min
Yu, Weiwei
Sun, Lisha
Chen, Qiu
author_facet Zhou, Dongqi
Zhang, Li
Han, Xuke
Gao, Yang
Zeng, Min
Yu, Weiwei
Sun, Lisha
Chen, Qiu
author_sort Zhou, Dongqi
collection PubMed
description BACKGROUND: Type 2 diabetes is a kind of metabolic disease. Its clinical characteristic is hyperglycemia. Recently, more and more elderly people suffer from type 2 diabetes, and the glycemic variability of the elderly is greater. In addition, blood sugar variation is more likely to cause diabetes complications than simple hyperglycemia. Sancai podwer (SC) is based on the theory of traditional Chinese medicine and gradually formed in the summary of clinical experience. It has the effect of lowering blood sugar and alleviating clinical symptoms of diabetes. But the existing evidence of its efficacy on glycemic variability is insufficient. So, in our study, the randomized controlled trials will be used as a research method to explore the effects of SC on glycemic variability of type 2 diabetes. METHOD: We will use randomized controlled experiments based on the recommended diagnostic criteria, inclusion and exclusion criteria. A total of 60 elderly patients with type 2 diabetes will be randomly divided into treatment group and control group, 30 cases in each group. The control group will receive conventional western medicine and the intervention group will receive SC combined with western medicine. The standard deviation and coefficient of variation of blood glucose level will be used as evaluation indexes. DISCUSSION: This study can provide evidence for the clinical efficacy and safety of SC in elderly patients with type 2 diabetes mellitus. TRIAL REGISTRATION: This study is registered on the Chinese Clinical Trial Registry: ChiCTR2000032611.
format Online
Article
Text
id pubmed-7402745
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-74027452020-08-05 The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial Zhou, Dongqi Zhang, Li Han, Xuke Gao, Yang Zeng, Min Yu, Weiwei Sun, Lisha Chen, Qiu Medicine (Baltimore) 3700 BACKGROUND: Type 2 diabetes is a kind of metabolic disease. Its clinical characteristic is hyperglycemia. Recently, more and more elderly people suffer from type 2 diabetes, and the glycemic variability of the elderly is greater. In addition, blood sugar variation is more likely to cause diabetes complications than simple hyperglycemia. Sancai podwer (SC) is based on the theory of traditional Chinese medicine and gradually formed in the summary of clinical experience. It has the effect of lowering blood sugar and alleviating clinical symptoms of diabetes. But the existing evidence of its efficacy on glycemic variability is insufficient. So, in our study, the randomized controlled trials will be used as a research method to explore the effects of SC on glycemic variability of type 2 diabetes. METHOD: We will use randomized controlled experiments based on the recommended diagnostic criteria, inclusion and exclusion criteria. A total of 60 elderly patients with type 2 diabetes will be randomly divided into treatment group and control group, 30 cases in each group. The control group will receive conventional western medicine and the intervention group will receive SC combined with western medicine. The standard deviation and coefficient of variation of blood glucose level will be used as evaluation indexes. DISCUSSION: This study can provide evidence for the clinical efficacy and safety of SC in elderly patients with type 2 diabetes mellitus. TRIAL REGISTRATION: This study is registered on the Chinese Clinical Trial Registry: ChiCTR2000032611. Wolters Kluwer Health 2020-07-31 /pmc/articles/PMC7402745/ /pubmed/32756078 http://dx.doi.org/10.1097/MD.0000000000020750 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3700
Zhou, Dongqi
Zhang, Li
Han, Xuke
Gao, Yang
Zeng, Min
Yu, Weiwei
Sun, Lisha
Chen, Qiu
The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial
title The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial
title_full The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial
title_fullStr The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial
title_full_unstemmed The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial
title_short The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial
title_sort effect of sancai powder on glycemic variability of type 2 diabetes in the elderly: a randomized controlled trial
topic 3700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402745/
https://www.ncbi.nlm.nih.gov/pubmed/32756078
http://dx.doi.org/10.1097/MD.0000000000020750
work_keys_str_mv AT zhoudongqi theeffectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT zhangli theeffectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT hanxuke theeffectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT gaoyang theeffectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT zengmin theeffectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT yuweiwei theeffectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT sunlisha theeffectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT chenqiu theeffectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT zhoudongqi effectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT zhangli effectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT hanxuke effectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT gaoyang effectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT zengmin effectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT yuweiwei effectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT sunlisha effectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial
AT chenqiu effectofsancaipowderonglycemicvariabilityoftype2diabetesintheelderlyarandomizedcontrolledtrial